--- title: "FDA NDA Acceptance and Strong RINGSIDE Data Support Immunome Buy Rating and Unchanged $40 Price Target" type: "News" locale: "en" url: "https://longbridge.com/en/news/292087841.md" description: "LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome (IMNM) with an unchanged $40 price target. The bullish stance is driven by the FDA's acceptance of the NDA for varegacestat, strong Phase 3 RINGSIDE data showing superior efficacy, and solid pipeline execution. Additionally, J.P. Morgan also issued a Buy rating on June 29." datetime: "2026-07-08T13:35:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292087841.md) - [en](https://longbridge.com/en/news/292087841.md) - [zh-HK](https://longbridge.com/zh-HK/news/292087841.md) --- # FDA NDA Acceptance and Strong RINGSIDE Data Support Immunome Buy Rating and Unchanged $40 Price Target LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IMNM stock, giving a Buy rating on June 29. ### 4th of July Sale - 70% Off - Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. - Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Charles Zhu has given his Buy rating due to a combination of factors tied to Immunome’s lead asset and overall execution. He highlights that the FDA’s acceptance of the NDA for varegacestat, with a standard review and an April 28, 2027 PDUFA date, locks in a clear path to potential commercialization in desmoid tumors and confirms the program is progressing as planned. Zhu also points to the strong Phase 3 RINGSIDE data for varegacestat, including robust response and progression-free survival metrics that he views as superior to the only approved oral GSI competitor, particularly given Immunome’s once-daily dosing profile. In addition, he underscores continued pipeline advancement across ADC programs and solid operational execution, supporting his unchanged $40 price target and reinforcing his conviction that Immunome offers attractive upside from current levels. Charles Zhu has given his Buy rating due to a combination of factors tied to Immunome’s lead asset and overall execution. He highlights that the FDA’s acceptance of the NDA for varegacestat, with a standard review and an April 28, 2027 PDUFA date, locks in a clear path to potential commercialization in desmoid tumors and confirms the program is progressing as planned. Zhu also points to the strong Phase 3 RINGSIDE data for varegacestat, including robust response and progression-free survival metrics that he views as superior to the only approved oral GSI competitor, particularly given Immunome’s once-daily dosing profile. In addition, he underscores continued pipeline advancement across ADC programs and solid operational execution, supporting his unchanged $40 price target and reinforcing his conviction that Immunome offers attractive upside from current levels. In another report released on June 29, J.P. Morgan also maintained a Buy rating on the stock with a $0.00 price target. ### Related Stocks - [IMNM.US](https://longbridge.com/en/quote/IMNM.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Charles Zhu Doubles Immunome Price Target to $40 on ADC Pipeline Progress and Favorable Risk‑Reward Profile](https://longbridge.com/en/news/289475996.md) - [Immunome (NASDAQ:IMNM) Insider Robert Lechleider Sells 55,000 Shares](https://longbridge.com/en/news/292044247.md) - [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md) - [This Analyst Just Cut Its Price Target on SNDK Stock. Here's Why.](https://longbridge.com/en/news/293654906.md) - [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)